ALX Oncology's Evorpacept Shows Promising, Durable Response in Advanced Breast Cancer Trial
Summary
ALX Oncology reported promising and durable response rates for its investigational drug evorpacept, in combination with zanidatamab, in patients with advanced HER2-positive breast cancer and high CD47 expression. This positive clinical data is a significant development for the small-cap biotech, especially following its recent highly dilutive $140.4 million equity offering and a prior decision not to pursue U.S. regulatory approval for another program. The "promising, durable response" suggests potential efficacy in a challenging patient population, which could significantly enhance the drug's commercial prospects and the company's valuation. Traders will be looking for further details on the trial data and the company's strategy for advancing evorpacept through later-stage clinical development and potential regulatory filings.
At the time of this announcement, ALXO was trading at $2.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $275.1M. The 52-week trading range was $0.40 to $2.66. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.